CI CI Cigna Group Loading... : Bullish and Bearish Analyst Opinions

Cigna at 200-week MA discount buy

Group life mortality runs well below target due to favorable working-age population mortality, but management flagged 2 points as transient prior-period development and expects normalization—early July shows reversion. — If mortality normalizes, insurers pricing off pandemic-era improvement face margin compression, while managed care beneficiaries (elderly) may see divergent trends.

Wall Street analysts issued a broad batch of upgrades, downgrades.

Management raised full-year EPS guidance citing strong first half performance and confidence in durable growth, though tempered by a 'prudent view' of the environment and intentions to reinvest.

Cigna Group reports second quarter 2026 revenue of 71.7 billion dollars and raises full-year.

Cigna reported second quarter 2026 adjusted earnings per share of $7.78 on revenue of $71.56.

Cigna reports Q2 2026 adjusted EPS of $7.78 and revenue of $71.56B, both beating estimates.

Cigna's new CEO Brian Evanko outlines a patient-centered strategy but faces challenges.

RBC initiates coverage of Centene with a Sector Perform rating and a price target of $70.

Cigna stable dividend payer.

Cigna undervalued at 9.7x earnings

Andy Constan notes that Cigna was drawn into the LTCM crisis due to inadequate hedging.

The speed of brand-to-biosimilar conversions at a large mail-order pharmacy customer was faster than anticipated, meaningfully reducing revenue growth but not operating income. — This suggests PBMs and mail-order pharmacies are insourcing biosimilar distribution faster than expected, which could pressure revenue for wholesale distributors but may not hurt their long-term profits.

CVS's Health Services segment pulled forward value from Q2 into Q1, masking some of the underlying rebate guarantee pressure, though the underlying business still modestly beat expectations. — Indicates timing dynamics within PBM earnings and the ongoing financial impact of rebate reform and transparency agreements.

Management is raising full-year guidance due to strong first-quarter performance, particularly in specialty care and pharmacy, indicating a confident outlook for the rest of the year.

Under my plan, I want to stop all payments to big insurance companies and instead give the money directly to the people so that they can buy their own healthcare. Managed care organizations derive a massive portion of their revenue and earnings from government-sponsored programs, including ACA subsidies, Medicare, and Medicaid. Cutting off direct federal payments to these insurers would severely compress their margins, disrupt their revenue base, and force a complete restructuring of the health insurance market. SHORT. The administration is actively targeting the profitability and government funding mechanisms of major managed care companies. Congress blocks the proposed healthcare overhaul, maintaining the status quo for managed care revenues and government subsidies.

Senator Marshall explicitly mentioned "clipping the wings of the Pharmacy Benefit Managers (PBMs)" and codifying "Trump Rx" / price transparency. PBMs (owned by major insurers like CVS, Cigna, UnitedHealth) rely on opaque pricing models for profit. Legislative momentum to force transparency or reduce their leverage acts as a regulatory headwind for these specific healthcare verticals. WATCH / AVOID PBM-exposed healthcare stocks. Gridlock in Congress prevents legislation from passing.

"I want to stop all payments to big insurance companies and instead give that money directly to the people... stock prices soared... like nothing else." The administration views the "middleman" model of Managed Care Organizations (MCOs) as the primary driver of healthcare inflation. Shifting federal subsidies (ACA/Medicare) directly to patients bypasses the insurers, threatening their revenue streams and margin compression. SHORT. The political target on the back of the insurance sector is now explicit policy. The lobby for healthcare insurers is powerful; implementation of direct payments may face logistical gridlock.

Management guides to at least 1.4% EPS growth in 2026, maintaining its long-term 10-14% growth algorithm despite PBM model investments and FTC-related transition. The tone is confident and proactive, emphasizing a clear model for navigating regulatory changes.

UnitedHealth explicitly forecasts a 10% Medicare Advantage medical cost trend for 2026, up from ~7.5% in 2025, citing elevated utilization and higher service intensity. This is a significant input cost pressure signal for the entire MA sector. — If the largest MA player's claims trend is accelerating to 10%, peers under-priced for 2026 will face adverse MLR surprises, pressuring their margins and potentially forcing them to cut benefits or exit markets in 2027.

1. THE FACT: Trump plans to meet with 14 insurance companies (including health, auto.

Express Scripts (ESI) customers are returning to Kroger pharmacies, directly boosting comparable sales and indicating restored contractual access.

Sell-off in health insurers is buying opportunity